Dianthus Therapeutics (DNTH)

• Market cap: $3.37B
• 1 day: -3.06%
• 5 days: -1.32%
• 1 month: 64.26%
• 3 months: 85.73%
• 6 months: 110.21%
• Year to date: 96.22%
• 1 year: 265.88%
• 5 years: -62.51%
• 10 years: -66.49%
• Sector: Healthcare
• Industry: Biotechnology

About: Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Employees: 78